Mersana Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2005-01-01

Employees: 123

Market Cap: $191.3M

Website: http://www.mersana.com

Clinical Trials

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

Phase 1

Completed

Conditions: Platinum Resistant Ovarian Cancer
Non-Small Cell Adenocarcinoma

Interventions: Drug: upifitamab rilsodotin

First Posted Date: 2024-07-24

Last Posted Date: 2024-07-24

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 142

Registration Number: NCT06517485

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer Metastatic
Platinum Resistant Ovarian Cancer

Interventions: Drug: upifitamab rilsodotin

First Posted Date: 2024-07-24

Last Posted Date: 2024-07-24

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 62

Registration Number: NCT06517433

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Phase 1

Recruiting

Conditions: HER2-positive Non-Small Cell Lung Cancer
HER2-positive Tumors
HER2 Low Breast Cancer
HER2-positive Gastric Cancer
HER2-positive Colorectal Cancer
HER2-positive Breast Cancer

Interventions: Drug: XMT-2056

First Posted Date: 2022-08-24

Last Posted Date: 2024-11-28

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 162

Registration Number: NCT05514717

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of South California, Los Angeles, California, United States

and more 6 locations

A Study of XMT-1660 in Participants With Solid Tumors

Phase 1

Recruiting

Conditions: Triple Negative Breast Cancer
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Ovarian Cancer
Adenoid Cystic Carcinoma
Primary Peritoneal Cavity Cancer

Interventions: Drug: XMT-1660

First Posted Date: 2022-05-17

Last Posted Date: 2024-03-20

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 319

Registration Number: NCT05377996

Locations: 🇺🇸
UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

and more 15 locations

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

Phase 3

Terminated

Conditions: Fallopian Tube Cancer
Primary Peritoneal Cancer
High Grade Serous Ovarian Cancer

Interventions: Other: Placebo
Drug: Upifitimab rilsodotin

First Posted Date: 2022-04-15

Last Posted Date: 2023-10-26

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 20

Registration Number: NCT05329545

Locations: 🇦🇺
Epworth Richmond, Richmond, Victoria, Australia
🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
Women's Cancer Center of Nevada, Las Vegas, Nevada, United States

and more 27 locations

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Phase 1

Terminated

Conditions: Platinum-sensitive Ovarian Cancer (UPGRADE-A)

Interventions: Drug: XMT-1536 (Upifitamab Rilsodotin)
Drug: Carboplatin

First Posted Date: 2021-06-01

Last Posted Date: 2023-10-10

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 31

Registration Number: NCT04907968

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Phase 1

Terminated

Conditions: Nonsmall Cell Lung Cancer
Ovarian Cancer

Interventions: Biological: XMT-1592

First Posted Date: 2020-05-20

Last Posted Date: 2024-03-15

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 31

Registration Number: NCT04396340

Locations: 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Phase 1

Active, not recruiting

Conditions: Non Small Cell Lung Cancer Metastatic
Platinum Resistant Ovarian Cancer

Interventions: Drug: upifitamab rilsodotin

First Posted Date: 2017-10-24

Last Posted Date: 2023-11-13

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 523

Registration Number: NCT03319628

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

Phase 1

Completed

Conditions: Advanced Breast Cancer
Advanced Nonsmall Cell Lung Cancer
Advanced Gastric Cancer

Interventions: Drug: XMT-1522

First Posted Date: 2016-11-02

Last Posted Date: 2021-02-24

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 120

Registration Number: NCT02952729

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 2 locations

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasm Metastasis

Interventions: Drug: XMT-1107

First Posted Date: 2009-11-11

Last Posted Date: 2018-01-31

Lead Sponsor: Mersana Therapeutics

Target Recruit Count: 52

Registration Number: NCT01011972

Locations: 🇺🇸
Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
🇺🇸
Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
🇺🇸
University of MD Greenbaum Cancer Center, Baltimore, Maryland, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy